Last reviewed · How we verify

NCT06574178

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

Recruiting now NA Last updated 18 February 2026
What this trial tests

NA trial testing Dietary Counseling in Psoriasis in 5 participants. Currently enrolling.

Timeline
1 January 2025
Primary endpoint
1 June 2026
1 September 2026

Quick facts

Lead sponsorUniversity of California, Davis
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment5
Start date1 January 2025
Primary completion1 June 2026
Estimated completion1 September 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, Davis

Who can join

18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Psoriasis is a chronic inflammatory disease that affects the skin and joints in 2-3 % of people in the United States. This inflammation of the skin, joints, and blood vessels in patients with psoriasis has been measured by older PET Scan technology but with limitations. With the new EXPLORER PET scanner technology, the investigators are testing to see if the EXPLORER is better than previous PET scanners and improve our ability to assess inflammation in patients. Also, it is known that the typical Western Diet - high in saturated fats, added sugars, and low in fiber - contributes to obesity and inflammation worldwide. There is evidence in animals that these signs of inflammation are reversible within 4 weeks when changed to a more balanced diet. Thus, this study aims to assess whether there are detectable decreases in inflammation of the skin and body of psoriasis patients who usually eat a Western Diet on an EXPLORER PET scan following 6 weeks of a more balanced diet.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Naturally derived bioactive compounds as precision modulators of immune and inflammatory mechanisms in psoriatic conditions.
    Radu A, Tit DM, Endres LM, Radu AF, et al · · 2025 · cited 13× · PMID 39576422 · DOI 10.1007/s10787-024-01602-z

Verify or expand the search:

Other trials of Dietary Counseling

Trials testing the same drug.

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

Other University of California, Davis trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06574178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing